COSMOS Pharmaceutical Corporation (3349.T)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Forecast and Price Target with Analyst Ratings, Revenue Estimates, and complete financial and advanced discounted cashflow forecasts for up to 10 years.

Trending:

COSMOS Pharmaceutical Corporation (3349.T) Stock Forecast & Price Prediction | Analyst Ratings

Revenue

1.05T

Lower than competitor

Worse than 3088.T's revenue of 1.06T.

Revenue Growth Rate

9.07%

Higher than competitor

Better than 3088.T's revenue growth rate of 3.82%.

EBITDA

63.04B

Lower than competitor

Worse than 3088.T's ebitda of 106.56B.

EBITDA Margin

5.99%

Lower than competitor

Worse than 3088.T's ebitda margin of 10.04%.

EBIT

41.90B

Lower than competitor

Worse than 3088.T's ebit of 83.96B.

EBIT Margin

3.98%

Lower than competitor

Worse than 3088.T's ebit margin of 7.91%.

Depreciation

21.14B

Lower than competitor

Better than 3088.T's depreciation of 22.60B.

Total Cash

65.50B

Lower than competitor

Worse than 3088.T's total cash of 111.75B.

Cash as Percentage of Revenue

6.22%

Lower than competitor

Worse than 3088.T's cash as percentage of revenue of 10.53%.

Receivables

2.89B

Lower than competitor

Better than 3088.T's receivables of 95.72B.

Receivables as Percentage of Revenue

0.27%

Lower than competitor

Better than 3088.T's receivables as percentage of revenue of 9.02%.

Inventories

91.02B

Lower than competitor

Better than 3088.T's inventories of 145.22B.

Inventories as Percentage of Revenue

8.65%

Lower than competitor

Better than 3088.T's inventories as percentage of revenue of 13.68%.

Accounts Payable

199.67B

Higher than competitor

Worse than 3088.T's accounts payable of 108.18B.

Payables as Percentage of Revenue

18.97%

Higher than competitor

Worse than 3088.T's payables as percentage of revenue of 10.19%.

Capital Expenditure

-51.69B

Lower than competitor

Better than 3088.T's capital expenditure of -8.83B.

CapEx as Percentage of Revenue

-4.91%

Lower than competitor

Better than 3088.T's capex as percentage of revenue of -0.83%.

Weighted Average Cost of Capital (WACC)

5.07%

Higher than competitor

Worse than 3088.T's weighted average cost of capital (wacc) of 4.93%.

Cost of Equity

5.18%

Higher than competitor

Worse than 3088.T's cost of equity of 4.93%.

Cost of Debt

3.99%

Equal to 3088.T's cost of debt of 3.99%.

Beta

0.25

Higher than competitor

Worse than 3088.T's beta of 0.17.

Diluted Shares Outstanding

79.24M

Lower than competitor

Better than 3088.T's diluted shares outstanding of 408.61M.

Total Debt

34.06B

Higher than competitor

Worse than 3088.T's total debt of 2.21B.

Total Equity

696.60B

Lower than competitor

Worse than 3088.T's total equity of 1.17T.

Total Capital

730.66B

Lower than competitor

Worse than 3088.T's total capital of 1.17T.

Debt Weighting

4.66%

Higher than competitor

Worse than 3088.T's debt weighting of 0.19%.

Equity Weighting

95.34%

Lower than competitor

Worse than 3088.T's equity weighting of 99.81%.

EBIAT

29.84B

Lower than competitor

Worse than 3088.T's ebiat of 54.72B.

Unlevered Free Cash Flow

23.87B

Lower than competitor

Worse than 3088.T's unlevered free cash flow of 59.63B.

Long-Term Growth Rate

2.00%

Lower than competitor

Worse than 3088.T's long-term growth rate of 3.00%.

Terminal Value

379.47B

Lower than competitor

Worse than 3088.T's terminal value of 2.82T.

Enterprise Value

352.79B

Lower than competitor

Worse than 3088.T's enterprise value of 2.45T.

Net Debt

-18.24B

Higher than competitor

Worse than 3088.T's net debt of -109.55B.

Equity Value

371.03B

Lower than competitor

Worse than 3088.T's equity value of 2.56T.

Equity Value Per Share

4682.41

Lower than competitor

Worse than 3088.T's equity value per share of 6262.50.

Select Metric for Chart